OVERVIEW

Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance is organized by Medical College of Wisconsin (MCW), PeerView Institute for Medical Education (PVI) and will be held from Mar 29, 2019 - Mar 28, 2020.

Target Audience:
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the management of patients with AML.

Accreditation:
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Description and Educational Objectives
In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease.

Upon completion of this activity, participants should be better able to:
• Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant
• Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML
• Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs

Additional details will be posted as soon as they are available.